Neoplasms by Site Clinical Trials

20 recruiting

Neoplasms by Site Trials at a Glance

20 actively recruiting trials for neoplasms by site are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in London, Manchester, and Houston. Lead sponsors running neoplasms by site studies include Cancer Research UK, Jiangxi Provincial Cancer Hospital, and Intuitive Surgical.

Browse neoplasms by site trials by phase

Treatments under study

About Neoplasms by Site Clinical Trials

Looking for clinical trials for Neoplasms by Site? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neoplasms by Site trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neoplasms by Site clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 1Phase 2

Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

Prostate CancerNeoplasmsNeoplasms by Site+7 more
Pathos AI, Inc.252 enrolled18 locationsNCT06785636
Recruiting
Phase 3

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Colorectal NeoplasmsNeoplasms by SiteGastrointestinal Neoplasms+7 more
Pfizer800 enrolled156 locationsNCT07222800
Recruiting
Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NeoplasmsNeoplasms by SiteBrain Diseases+30 more
M.D. Anderson Cancer Center24 enrolled3 locationsNCT03911388
Recruiting
Phase 1Phase 2

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

MalignancyMelanomaCancer+8 more
Cancer Research UK30 enrolled27 locationsNCT05770544
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

MalignancyMelanomaCancer+7 more
Cancer Research UK30 enrolled27 locationsNCT05770102
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

CancerRenal Cell CarcinomaLymphoma+8 more
Cancer Research UK30 enrolled27 locationsNCT05770037
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

MalignancyGastric CancerSoft Tissue Sarcoma+8 more
Cancer Research UK30 enrolled17 locationsNCT06988475
Recruiting

Real World Registry for Use of the Ion Endoluminal System

Lung CancerLung NeoplasmsNeoplasms+6 more
Intuitive Surgical3,000 enrolled16 locationsNCT06004440
Recruiting
Phase 2

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

NeoplasmsNeoplasms by SiteUrinary Bladder Neoplasm+8 more
The Netherlands Cancer Institute90 enrolled9 locationsNCT06237920
Recruiting
Phase 1

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

MelanomaNeoplasmsNeoplasms by Site+7 more
Yana Najjar50 enrolled2 locationsNCT04572451
Recruiting
Phase 1Phase 2

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Advanced Solid TumorsCarcinomaNeoplasms+9 more
Marengo Therapeutics, Inc.365 enrolled32 locationsNCT05592626
Recruiting
Not Applicable

Early Intervention Strategies for Lung Cancer

Lung NeoplasmsNeoplasmsNeoplasms by Site+4 more
The First Affiliated Hospital of Guangzhou Medical University16,000 enrolled1 locationNCT06988943
Recruiting
Not Applicable

Research Project on Reminders and Self-Sampling Can Increase Participation in Gynecology Cell Sampling - Preventive Examination Against Cervical Cancer.

Cervical CancerNeoplasmsNeoplasms by Site+7 more
Karolinska Institutet20,000 enrolled6 locationsNCT04061967
Recruiting
Phase 4

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

NeoplasmsMetastatic Prostate CancerNeoplasms by Site+8 more
VA Greater Los Angeles Healthcare System15 enrolled1 locationNCT06706921
Recruiting

OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.

NeoplasmsNeoplasms by SitePancreatic Neoplasm+5 more
OncoSil Medical Limited500 enrolled9 locationsNCT04493632
Recruiting
Not Applicable

Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.

Head and Neck NeoplasmsEsophageal NeoplasmsNeoplasms+6 more
Taipei Veterans General Hospital, Taiwan20 enrolled1 locationNCT06365866
Recruiting
Phase 2

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

Lung NeoplasmsNeoplasmsNeoplasms by Site+7 more
Nanfang Hospital, Southern Medical University62 enrolled1 locationNCT06177925
Recruiting

Spanish Series of Patients Treated With the Radionuclide Lutetium177

Stomach NeoplasmsNeuroendocrine TumorsNeoplasms+15 more
Sociedad Española de Medicina Nuclear e Imagen Molecular5,000 enrolled20 locationsNCT04949282
Recruiting
Phase 2

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

Esophageal Squamous Cell CarcinomaEsophageal NeoplasmsNeoplasms by Site+8 more
Jiangxi Provincial Cancer Hospital30 enrolled1 locationNCT05252078